

### ACHA SEXUAL HEALTH SERVICES SURVEY 2018

### **American College Health Association**

### **Sexual Health Services Survey for Calendar Year 2017**

Thank you for taking the time to complete this survey. We have changed the name of the ACHA Pap Test and STI Survey to the Sexual Health Services Survey in an effort to be more inclusive and more accurately reflect the information collected. The ACHA Sexual Health Education and Clinical Care Coalition has made significant revisions to the survey to make it as concise and easy-to-follow as possible. The objective of this survey is to track modes of management and outcomes of evaluation to serve as both a benchmark and database of comparable statistics.

All data collected in this survey is in reference to Calendar Year 2017 (January 1 – December 31, 2017). Please answer with respect to services you provided and policies that were in place in CY2017, rather than current policies or practices.

Please submit only objective data except as specified. Please leave blank unanswerable questions or questions that are not applicable to your health services. DEADLINE: September 15, 2018.

Use only whole numbers in your numerical entries (no commas).

You are encouraged to print this survey prior to completing online survey to use as a worksheet. Submit the completed online survey data one time only.

#### **Contact and Demographics**

Name of College/University:

1)	Name of person completing this survey:	
2)	Title of person completing this survey:	
3)	E-mail address for questions about survey entries:	
4)	Telephone number of respondent:	
5)	Which best describes your <u>primary</u> role in college health?	
	O Administrator	
	O Healthcare Provider	
	Information Technology or Data Management	
	O Health Education/Promotion Professional	
	O Other (please specify)	

### 6) College Health Center demographic information (for the percentages enter a whole number only)

- \_\_\_\_\_ Total number of student medical visits to your Health Center 2017
- \_\_\_\_\_ % female visits
- \_\_\_\_\_% male visits
- \_\_\_\_\_\_% transgender or gender non-conforming visits

# 7) Sexual health visits in 2017 (GYN exam, annual/well woman exam, STI

screening/treatment, PrEP, hormone therapy, etc.) were conducted in the following clinical settings.

	Yes	No
Primary Care	$\bigcirc$	$\bigcirc$
Clinic dedicated to GYN or Sexual Health	$\bigcirc$	0
Other (please specify)	$\bigcirc$	0

#### **Cervical Cancer Screening and Management**

Cervical cancer screening and management assumptions about standard of care are based on the following:

Guidelines for the Management of Women with Abnormal Cervical Cancer Screening Tests Saslow D, Solomon D, Lawson H, et al. (2012).

American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. *Journal of Lower Genital Tract Disease*, 16(3).

Massad LS, Einstein M, Huh W, wt al. (2013). 2012 Updated Consensus Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. *Journal of Lower Genital Tract Disease*, 17(5); S1-27.

For more information go to: <u>http://www.asccp.org/asccp-guidelines</u>

8) For each age group, indicate whether or not this cervical cytology screening test was provided for female persons or persons with a cervix at your health center in 2017.

	Ages 21-24		21-24 Ages 25-29		Ages 30-65	
	Yes	No	Yes	No	Yes	No
Conventional slide	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Liquid-based cytology, alone	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Liquid-based cytology with reflex HPV testing for ASC-US or LSIL	0	$\bigcirc$	$\bigcirc$	0	$\bigcirc$	0
Liquid-based cytology with HPV "co- testing"	0	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
None, these were not offered by our health service	0	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
	0	Ŭ	Ŭ	Ŭ	Ŭ	$\bigcirc$

9) Please indicate which of the following cervical disease management modalities were provided in-house at your Health Center in 2017.

. ,	Provided at our Health Center	Not provided at our Health Center (patients referred to outside provider)
Colposcopy	$\bigcirc$	$\bigcirc$
Cryotherapy	$\bigcirc$	$\bigcirc$
Laser ablation/LEEP	$\bigcirc$	$\bigcirc$
Other (please specify)	0	0

10) For women under age 25, what was your Health Center's usual practice for management of a first screening Pap test reported as atypical squamous cells of undetermined significance (ASC-US) in 2017? (select one)

- O HPV DNA test (reflex or otherwise)
- O Repeat Pap in 6 months
- O Repeat Pap in 12 months
- O Immediate colposcopy
- O Varied by provider, no standard practice
- O Don't know

11A) Summary of all Cervical Pap test results for January 1, 2017-December 31, 2017 (Results in items Q11A through Q11G are mutually exclusive and SHOULD SUM TO EQUAL THE TOTAL REPORTED at the bottom row labeled TOTAL. Please make sure to enter data in 11A-G below so that we can calculate correct rates for each category of test result.

A. Number reported as normal :

B. Number reported as ASC-US (atypical squamous cells of undetermined significance) :

C. Number reported as LSIL (low-grade squamous intraepithelial lesion) :

D. Number reported as ASC-H, Low-grade, cannot exclude high-grade or HSIL or CIS (atypical squamous cells: cannot exclude high-grade, high-grade squamous intraepithelial lesion) :

E. Number reported as AGC or CIS (atypical glandular cells or carcinoma in situ) :

F. Number reported as unsatisfactory (no dx) :

G. Number reported as other dx, not listed above :

Total :

#### 11B ) Summary of all Cervical Pap test results for January 1, 2017-December 31, 2017.

\_\_\_\_ Number reported with <u>no endocervical cells present</u> (with any dx above)

#### **STI Testing**

12) Did your health center require a provider (MD, NP, PA) visit in 2017 for STI screening (i.e. labs) in asymptomatic patients?

◯ Yes

O No, we do not require a provider visit for STI screening labs in asymptomatic patients

O No, STI screening was not provided for any students at our health center

I don't know

## 12A) Please indicate which of the following STI(s) screening was provided in 2017 without requiring a visit with a provider (MD, NP, PA) for asymptomatic patients?

	Yes	No
Chlamydia	$\bigcirc$	$\bigcirc$
Gonorrhea	0	$\bigcirc$
HIV	$\bigcirc$	$\bigcirc$
Syphilis	$\bigcirc$	$\bigcirc$
Other (specify):	0	$\bigcirc$

#### 13A) Chlamydia testing

O Number of unique (unduplicated) female patients under age 26 seen at your health center in 2017.

#### 13B) Chlamydia testing

#### Note that 13B must be less than or equal to 13A

O Number of unique (unduplicated) female patients under age 26 tested for chlamydia at your health center in 2017.

14) What type of specimen did your Health Center usually/preferentially collect for chlamydia testing in females in 2017? (select one)

	○ Cervical swab
	○ Vaginal swab-Patient collected
	◯ Vaginal swab-Clinician collected
	◯ Varies
	○ None
_	

15) What type of specimen did your Health Center usually/preferentially collect for chlamydia testing in males in 2017? (select one)

◯ Urethral swab	
○ Varies	
○ None	

16) What type of specimen did your Health Center usually/preferentially collect for chlamydia testing in individuals who do not identify as male or female in 2017? (select one)

○ Cervical swab
○ Vaginal swab-Patient collected
◯ Vaginal swab-Clinician collected
O Urethral swab
○ Varies
○ None

16A) Did your health center routinely include pharyngeal and rectal tests for chlamydia and gonorrhea when screening the following groups for STIs in 2017?

	Men wh sex wit		Women w sex with		Women w sex wit		Men wh sex with	
	Yes	No	Yes	No	Yes	No	Yes	No
Chlamydia	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Gonorrhea	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

### 17) Which of the following statements best describes how the cost of STI screening was covered at your health service in 2017? (select one)

All tests/visits were charged to the patient or their insurance (there was always a cost to the patient or their insurance)

O Some tests/visits were charged but others are free (there was sometimes a cost to the patient or their insurance)

All tests/visits were free to the student (there was never a cost to the patient or their insurance)

• None of the above or not applicable

Other (please specify) \_\_\_\_\_

## 18) What types of HIV antibody tests did your Health Center usually/preferentially collect to screen for HIV in 2017? (select one)

C Laboratory test, blood
C Laboratory test, oral fluid
◯ Rapid test, blood
◯ Rapid test, oral fluid
○ None
O Other (please specify)
19) Did your Health Center offer PrEP (Pre-Exposure Prophylaxis) in CY 2017?
○ Yes
○ No
◯ I don't know
19A) For those who prescribed PrEP in CY 2017, what percent were the following:
Men who have sex with men :
Heterosexual men :
Heterosexual women : People who inject drugs :
Other (please specify) :

Total : \_\_\_\_\_

19B) For those patients who were initiated on PrEP in 2017, what percent returned for a 3-month follow-up appointment:

0-24%		
25-49%		
50-74%		
75-99%		
0 100%		

19C) For those not prescribing PrEP in 2017, what were the barriers to prescribing: (please select all that apply)

Lack of training/knowledge
Lack of administrative support
We don't prescribe any medications
Religious objections
Other (please specify)

20) Did your Health Center offer <u>non-occupational</u> PEP (Post-Exposure Prophylaxis) in 2017?

$\bigcirc$	Yes
$\cap$	No

 $\sim$ 

⊖ No

I don't know

\_\_\_\_\_

21) What laboratory test did your Health Center usually/preferentially use to diagnose genital herpes infection in 2017? (select one):

○ Viral culture
○ PCR
<ul> <li>Type specific serology (antibody testing)</li> </ul>
O Antigen tests
C Tzank smears
Other (please specify)

## 22) What type of test did your Health Center usually/preferentially use for the diagnosis of trichomoniasis infection in women in 2017? (select one)

O Microscopy (wet prep)
○ Culture
<ul> <li>Antigen detection ( e.g. OSOM or Affirm)</li> </ul>
○ PCR or other NAAT ( e.g. APTIMA or Amplicor)
O Other (please specify)

#### STI TEST RESULTS

Instructions: Please make sure to enter corresponding data in questions below so that we can calculate positivity rates by sex. For sex, use sex assigned at birth for those not identifying as transgender. If you do not collect data by sex, please report totals in the "unknown" category for each infection. The number of positive test results must always be equal to or less than the number of tests done for each infection. All data applies to tests performed by your health service in calendar year 2017.

23)	Number of Gonorrhea tests performed, by sex in 2017
	Females
	Males
	Transgender
	Unknown/unspecified gender

#### 24) Number of Gonorrhea tests positive, by sex in 2017

Females
 Males
 Transgender
 Unknown/unspecified gender


#### 25) Number of Chlamydia tests performed, by sex in 2017

- \_\_\_\_\_ Females
- \_\_\_\_\_ Males
- \_\_\_\_\_ Transgender
- \_\_\_\_\_ Unknown/unspecified gender

#### 26) Number of Chlamydia tests positive, by sex in 2017

- \_\_\_\_\_ Females
- \_\_\_\_\_ Males
- \_\_\_\_\_ Transgender
  - \_\_\_\_\_ Unknown/unspecified gender

#### 27) HIV antibody tests performed, by sex in 2017

- \_\_\_\_\_ Females
- \_\_\_\_\_ Males
- \_\_\_\_\_ Transgender
- \_\_\_\_\_ Unknown/unspecified gender

#### 28) HIV antibody tests positive, by sex in 2017

\_\_\_\_\_Females

\_\_\_\_\_ Males

\_\_\_\_\_ Transgender

\_\_\_\_\_ Unknown/unspecified gender

#### 29) Syphilis tests performed, by sex in 2017

\_\_\_\_\_ Females

\_\_\_\_\_ Males

\_\_\_\_\_ Transgender

\_\_\_\_\_ Unknown/unspecified gender

\_\_\_\_\_

#### **30)** Syphilis tests positive, by sex in 2017

\_\_\_\_\_ Females

\_\_\_\_\_ Males

\_\_\_\_\_ Transgender

\_\_\_\_\_ Unknown/unspecified gender

31)	Herpes viral culture or PCR tests performed in 2017 (genital sites only):
	Females
	Males
	Individuals who do not identify as either male or female

#### 32) Herpes viral culture or PCR tests performed in 2017 for <u>females</u> (genital sites only):

### Please double check that your total in 32 is equal to or less than the total you reported for <u>females</u> in 31.

Total number positive for HSV-2 :	
Total number positive for HSV-1 :	
Total number positive type unknown :	
Total :	

33) Herpes viral culture or PCR tests performed in 2017 for <u>males</u> (genital sites only):

Please double check that your total in 33 is equal to or less than the total you reported for <u>males</u> in 31.

Total number positive for HSV-2 :	
Total number positive for HSV-1 :	
Total number positive type unknown : _	
Total :	

34) Herpes viral culture or PCR tests performed in 2017 for individuals who <u>do not</u> <u>identify as either male or female</u> (genital sites only):

Please double check that your total in 34 is equal to or less than the figure you reporte	d
for those who <u>do not identify as either male or female</u> in 31.	

Total number positive for HSV-2 :	
Total number positive for HSV-1 :	
Total number positive type unknown :	
Total :	

-	many patients did your Health Center diagnose with trichomoniasis in 2017? Patients
36) How	many patients did your Health Center diagnose with bacterial vaginosis in 2017?
	Patients
	ber of unduplicated patients diagnosed with genital warts in 2017: Females Males
	_ Indies _ Transgender _ Unknown/unspecified gender
	your health center provide anal cytology screening for any of the following als in 2017? Check all that apply.

Females
Males
Transgender
Unknown/gender unspecified
None, we don't perform anal cytology at our Health Center
don't know

39) If yes, number of anal cytology tests performed in 2017:

Number of females
Number of males
Number of transgender
Number of unknown/gender unspecified

40) Did providers (MD, NP, PA) at your Health Center prescribe hormone therapy for transgender patients in 2017?

○ Yes

🔿 No

O I don't know

40A) In 2017, we offered the following hormone therapy for transgender patients:

Initiated therapy only
 Initiated and continued therapy
 Continued therapy only

## 40B) What were barriers to prescribing hormone therapy for transgender patients in 2017? (please select all that apply)

Lack of training/knowledge
Lack of administrative support
We don't prescribe any medications
Religious objections
Other (please specify)

41) Did the laws in the state your Health Center is located and your health center's policy permit providers to provide expedited partner therapy (EPT) for treatment of any of the following STIs in 2017?

Chlamydia	W
Gonorrhea	
Syphilis O O O O	
Trichomoniasis	
Other (please specify)	

#### 42) What is your level of agreement with the following statement?

"In 2017, patients at our health or wellness center regularly voiced concerns that their parent(s) may find out that they received testing, screening, or treatment for a sexually transmitted infection (STI), including HIV."

$\bigcirc$	Strongly	agree
------------	----------	-------

○ Agree

O Neutral/Indifferent

O Disagree

O Strongly disagree

43) In 2017, did your state law allow students to have their explanation of benefit (EOB) forms sent directly to them?

◯ Yes

🔿 No

O I don't know

# 44) Regarding STIs and patient confidentiality concerns, please indicate which of the following procedures were used in your center between January 1 and December 31, 2017.

	Yes	No	l don't know
We offered anonymous and/or confidential HIV testing.	$\bigcirc$	$\bigcirc$	$\bigcirc$
We referred patients to other health care providers that offered confidential screening, testing, or treatment for free or reduced cost.	0	$\bigcirc$	$\bigcirc$
Student health fees covered STI/HIV testing, screening, and/or treatment services, so there was no additional cost to students.	0	$\bigcirc$	$\bigcirc$
We (or another university office) hosted at least one campus testing event that offered free and anonymous and/or confidential testing. (e.g., Get Yourself Talking, Get Yourself Tested).	0	$\bigcirc$	$\bigcirc$
Patients could pay for testing, screening, or treatment out of pocket to avoid having an explanation of benefits (EOB) form generated.	0	$\bigcirc$	$\bigcirc$
We did not generate EOB forms as we do not bill third-party health insurance.	$\bigcirc$	$\bigcirc$	$\bigcirc$
We billed third-party health insurance using more general billing codes.	$\bigcirc$	$\bigcirc$	$\bigcirc$
We explained to patients that receiving any testing, screening, or treatment was not confidential and may be revealed on EOB forms that are sent to insurance policy holders.	0	$\bigcirc$	0
EOB forms were sent directly to students' local addresses.	0	$\bigcirc$	$\bigcirc$
We did not have any of the above procedures in place.	0	$\bigcirc$	$\bigcirc$

45) Other procedures that your center employed in 2017 to ensure confidentiality related to STI testing, screening, or treatment:

46) On which of the following topics did your health center provide information to students in 2017? This includes any clinical service, health education sessions, etc. (Check all that apply) Abstinence Consent Contraception Emergency Contraception External (male) condom use Fertility awareness methods General family planning/Preconception Healthy Relationships Gender Identity and Sexual Orientation Internal (female) condom use Sexual assault awareness/prevention STI/HIV prevention Other (please specify) \_\_\_\_\_

### 47) Was OTC Emergency Contraception (Plan B) available through your Student Health Service in 2017?

○ Yes, for free

- Yes, at some cost
- Yes, both free and at some cost

O No, it was not available for students through our Student Health Service

\_\_\_\_\_

## 48) Was prescription Emergency Contraception (Ella) provided through your Student Health Service in 2017?

○ Yes, it was prescribed by our clinicians and dispensed through SHS

○ Yes, it was prescribed by our clinicians but not dispensed through SHS

O No, it was not prescribed by our clinicians or dispensed through SHS

## 49) Was copper IUD for Emergency Contraception (Paragard) provided through your Student Health Service in 2017?

○ Yes, it was provided through our SHS for Emergency Contraception

○ No, it was not provided through our SHS for Emergency Contraception; patients are referred to outside provider

○ No, it was not provided through our SHS for Emergency Contraception and patients are not referred to outside provider

50A) Please answer the following questions about the availability of safer sex products and contraceptive methods through your Student Health Service in 2017:

OTC Items	How were the following items made available to students in 2017?			
	For free	At some cost	Both free and at some cost	Item not available to students
Female (internal) condom	0	$\bigcirc$	$\bigcirc$	0
Latex, or non- latex dams (i.e., dental or oral dams)	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Latex, or non- latex gloves	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Lubricant	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Male (external) condom	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Spermicides (suppositories, foams, jellies and vaginal contraceptive film)	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

#### **RX/Patient-administered methods**

	Was the medication/device prescribed by SHS provider in 2017?		Was the medi dispensed from th	
	Yes	No	Yes	No
Cervical Cap	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Contraceptive Patch	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Contraceptive Ring	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Diaphragm	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Oral contraceptives (combined and mini pill)	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

#### **RX/Provider-administered methods**

	Was the medication/device/procedure provided at the SHS in 2017?		Were interestered off-car medication/devic 2017	npus for this e/procedure in
	Yes	No	Yes	No
Depo Provera	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Essure	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Implants (Implanon/Nexplanon)	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Intrauterine devices (hormonal or copper)	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Tubal Ligation	0	$\bigcirc$	$\bigcirc$	0
Vasectomy	0	$\bigcirc$	$\bigcirc$	$\bigcirc$

### 51) For pregnancy tests performed at your health center between January 1, 2017 to December 31, 2017 (in-house or sent out, either urine or blood):

Please double check that your number of positive tests is not greater than the number of tests performed.

\_\_\_\_\_ Number performed \_\_\_\_\_ Number positive 52) For students with a positive pregnancy test, what services were available from your Health Center in 2017?

	Yes	No	No, not permitted due to legal limitations in our state	No, not permitted due to school policy
"All options" counseling and education	0	$\bigcirc$	0	0
Limited counseling and education	$\bigcirc$	0	$\bigcirc$	$\bigcirc$
Referral for adoption services	$\bigcirc$	0	$\bigcirc$	$\bigcirc$
Referral for abortion services	$\bigcirc$	0	$\bigcirc$	$\bigcirc$
Referral for prenatal care	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Medical abortion services provided at SHS	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Prenatal care provided at SHS	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

53) In 2017, did your health center use chaperones (a person who serves as a witness for both a patient and the medical provider) as a safeguard for all parties during sensitive medical examinations or procedures?

◯ Yes		
○ No		
O I don't know		

54) Did your organization's (electronic) health record provide standard options for collecting BOTH the patient's gender identity <u>and</u> sex assigned at birth in 2017? (Free-form notes would not count.)

$\bigcirc$	Yes
$\bigcirc$	103

○ No

O I don't know

55) Did your organization's (electronic) health record provide standard options for collecting the patient's sexual orientation in 2017? (free-form notes, and questions about sexual <u>behaviors</u> would not count.)

◯ Yes

🔿 No

O I don't know

Contact <u>Mary Hoban</u> at ACHA for specific questions about this survey. Thank you for taking the time to complete this survey.

When you hit the "submit" button below, your responses will be recorded and a summary of your submission will be displayed. You may download a PDF of your submission for your records.

Once the survey closes, data will be compiled and sent to the email address provided in the survey. The results will subsequently be posted on the ACHA website.